Tempus AI announced a major partnership with Daiichi Sankyo today. Consequently, this collaboration advances AI-Driven Biomarker Discovery. Furthermore, it accelerates an important oncology antibody drug conjugate program.
Daiichi Sankyo will leverage Tempus’ advanced artificial intelligence models. Specifically, the advanced PRISM2 foundation model will be used. This powerful tool combines pathology images with clinical data. As a result, it generates rich predictive and diagnostic insights.
Next, the partners will merge their vast information datasets. Daiichi Sankyo provides clinical trial and preclinical research data. Meanwhile, Tempus supplies its comprehensive real-world evidence database. Together, they will unlock new patient stratification opportunities.
Additionally, the teams will build proof-of-concept AI models. These tools will significantly optimize future patient selection processes. Ultimately, they aim to increase success rates for novel ADCs. Moreover, the collaboration will generate detailed patient response maps. Thus, researchers can establish rigorous benchmarks for clinical trials.
“Our collaboration with Daiichi Sankyo signals a new chapter in how multimodal AI and real-world data can be applied to advance the development of ADCs,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “Our multimodal foundation models seek to radically accelerate and improve our ability to uncover unmet patient needs and identify patients most likely to benefit from novel therapies. Applying AI in clinical development isn’t just about efficiency anymore, leading companies like Daiichi Sankyo are using these models to enhance the design of more targeted, impactful clinical trials.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
